NCT03935217View on ClinicalTrials.gov

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

March 2, 2020

Study Completion Date

March 25, 2020

Conditions
Trichomonas Infection
Interventions
DRUG

Secnidazole

Oral Granules containing secnidazole

DRUG

Placebo

Oral Granules of placebo manufactured to mimic secnidazole

Trial Locations (11)

23456

Site 1006, Virginia Beach

27599

Site 1008, Chapel Hill

28304

Site 1004, Fayetteville

29425

Site 1011, Charleston

33161

Site 1003, North Miami

35294

Site 1007, Birmingham

38104

Site 1001, Memphis

38120

Site 1002, Memphis

39216

Site 1013, Jackson

60605

Site 1014, Chicago

08648

Site 1009, Lawrenceville

Sponsors

Lead Sponsor

Lupin Research Inc
All Listed Sponsors
lead

Lupin Research Inc

INDUSTRY

NCT03935217 - A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis | Biotech Hunter | Biotech Hunter